The substantia nigra ("black substance") is the paired midbrain nucleus darkened by neuromelanin — the by-product of the dopamine its neurons make. Two parts, two jobs: the pars compacta sends dopamine up the nigrostriatal pathway to the striatum, the movement-enabling signal whose degeneration causes Parkinson's disease; the pars reticulata is, with the internal globus pallidus, an output gate of the basal ganglia, holding eye and body movements in check until released.
Location
Ventral midbrain, dorsal to the cerebral peduncles
Key Components
Pars compacta (dopaminergic, pigmented), pars reticulata (GABAergic output), pars lateralis
Main Connections
Nigrostriatal dopamine to putamen/caudate; SNr to thalamus and superior colliculus
Chief Neurotransmitters
Dopamine (SNc), GABA (SNr)
Primary Role
Motor enabling, action selection, reward learning
Structure & Location
SNc dopamine neurons have enormous axonal arbors — each supplying hundreds of thousands of striatal synapses — and pacemaking calcium currents that load their mitochondria: anatomy that makes them vulnerable.
Neuromelanin accumulates with age, visible to the naked eye at autopsy and now to neuromelanin-sensitive MRI as a Parkinson's biomarker.
SNr's tonically-firing GABAergic neurons hold the thalamus and superior colliculus under inhibition — saccade control's gate.
Circuitry & Connections
Nigrostriatal pathway: SNc → dorsal striatum, the motor and habit dopamine supply (A9 cell group); the adjacent VTA (A10) feeds the limbic striatum.
Striatonigral feedback: direct-pathway MSNs inhibit SNr, and striosomes project back to SNc — the loop that lets the striatum regulate its own dopamine.
SNr outputs reach the motor thalamus and brainstem — the basal ganglia's alternative exit beside GPi.
Function
Movement vigor: dopamine sets the gain on movement — speed and amplitude — the bradykinesia of its loss shows what it normally provides.
Learning: phasic dopamine bursts at unexpected rewards (and dips at omission) teach the striatum — the prediction-error signal.
Eye movements: SNr's pause releases the superior colliculus for saccades — the oculomotor arm of action selection.
Clinical Relevance
Parkinson's disease: symptoms appear after ~50–60% SNc neuron loss (and more striatal terminal loss) — Lewy bodies of α-synuclein mark the cells; levodopa, dopamine agonists, MAO-B inhibitors, and DBS treat it.
Drug-induced parkinsonism: D2-blocking antipsychotics and MPTP (the designer-drug contaminant that founded modern Parkinson's research).
Imaging: DaT-SPECT and neuromelanin MRI distinguish degenerative parkinsonism from mimics.